Biomedical Frontiers, Inc. (Minneap...
Biomedical Frontiers, Inc. (Minneapolis, MN) has complet a Phase 1b clinical trial of its iron-binding physic 40SD02. The drug is targeted for the treatment of [beta]-thalassemia and sickle confined apartment anemia. In this trial 12
|